Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation.
ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapy for hematological malignancies and inherited diseases. However, acute graft-versus-host-disease (aGVHD) is a major life-threatening complication after allo-HCT and there are few therapeutic options for severe steroid-refractory aGVHD. Preliminary studies on co-transplantation of mesenchymal stem cells (MSCs) have shown an improvement in or resolution of severe aGVHD. However, the mechanism underlying this immunosuppressive effect has not been elucidated. Most of the data suggest that the immunosuppressive effect involves soluble factors such as IL-6 or TGF-beta as well as cell-cell contact dependence. MSCs interact either directly with T cells or indirectly via other immune cells such as dendritic cells and NK cells. Here we review the immunomodulatory function of MSCs in allo-HCT and their potential usefulness in the treatment or prevention of severe acute GVHD.
- SourceAvailable from: PubMed Central[show abstract] [hide abstract]
ABSTRACT: Objective: Graft-versus-host disease (GVHD) is a major obstacle to successful allogeneic bone marrow transplantation (allo-BMT). While multipotent mesenchymal stromal cells (MSCs) demonstrate alloresponse in vitro and in vivo, they also have clinical applications toward prevention or treatment of GVHD. The aim of this study was to investigate the ability of MSCs to prevent or treat GVHD in a rat BMT model. Materials and Methods: The GVHD model was established by transplantation of Sprague Dawley rats' bone marrow and spleen cells into lethally irradiated (950 cGy) SDxWistar rat recipients. A total of 49 rats were randomly assigned to 4 study and 3 control groups administered different GVHD prophylactic regimens including MSCs. After transplantation, clinical GVHD scores and survival status were monitored. Results: All irradiated and untreated control mice with GVHD died. MSCs inhibited lethal GVHD as efficiently as the standard GVHD prophylactic regimen. The gross and histopathological findings of GVHD and the ratio of CD4/CD8 expression decreased. The subgroup given MSCs displayed higher in vivo proportions of CD25+ T cells and plasma interleukin-2 levels as compared to conventional GVHD treatment after allo-BMT. Conclusion: Our results suggest that clinical use of MSCs in both prophylaxis against and treatment of established GVHD is effective. This study supports the use of MSCs in the prophylaxis and treatment of GVHD after allo-BMT; however, large scale studies are needed. Conflict of interest:None declared.Turkish Journal of Haematology 09/2013; 30(3):256-62. · 0.49 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: In the last 10 years, mesenchymal stem cells (MSCs) have emerged as a therapeutic approach to regenerative medicine, cancer, autoimmune diseases, and many more due to their potential to differentiate into various tissues, to repair damaged tissues and organs, and also for their immunomodulatory properties. Findings in vitro and in vivo have demonstrated immune regulatory function of MSCs and have facilitated their application in clinical trials, such as those of autoimmune diseases and chronic inflammatory diseases. There has been an increasing interest in the role of MSCs in allogeneic hematopoietic stem cell transplantation (HSCT), including hematopoietic stem cell engraftment and the prevention and treatment of graft-versus-host disease (GVHD), and their therapeutic potential has been reported in numerous clinical trials. Although the safety of clinical application of MSCs is established, further modifications to improve their efficacy are required. In this review, we summarize advances in the potential use of MSCs in HSCT. In addition, we discuss their use in clinical trials of the treatment of GVHD following HSCT, the immunomodulatory capacity of MSCs, and their regenerative and therapeutic potential in the field of HSCT.Experimental & molecular medicine. 01/2013; 45:e2.
- [show abstract] [hide abstract]
ABSTRACT: Mesenchymal stem cells (MSCs) have immunosuppressive activity. They do not induce allospecific T cell responses, making them promising tools for reducing the severity of graft versus host disease (GVHD) as well as treating various immune diseases. Currently, there is a need in the MSC field to develop a robust in vitro bioassay which can characterize the immunosuppressive function of MSCs. Murine clonal CD4 and CD8 T cells were stimulated with cognate peptide antigen and antigen presenting cells (APCs) in the absence or presence of human MSCs, different aspects of T cell activation were monitored and analyzed using flow cytometery, real time RT-PCR and cytokine measurement. Human MSCs (hMSCs) can alter multiple aspects of murine T cell activation induced by stimulation with specific antigen, including: reduced proliferation, inhibited or stimulated cell surface marker expression (CD25, CD69, CD44 and CD62L), inhibited mRNA expression of transcription factors (T-bet and GATA-3) and decreased cytokine expression (interferon-gamma, interleukin-10). Disappearance of activation-induced cluster formation and decreased apoptosis of CD8 T cells were also observed. Moreover, the effects are specific to MSCs; incubating the T cells with non-MSC control cell lines had no effect on T cell proliferation and activation. Clonal murine T cells can be used to measure, characterize, and quantify the in vitro immunosuppressive activity of human MSCs, representing a promising approach to improve bioassays for immunosuppression.Stem Cell Research & Therapy 01/2013; 4(5):128. · 3.65 Impact Factor
252 Current Stem Cell Research & Therapy, 2009, 4, 252-259
1574-888X/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd.
Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-
Host Disease After Allogeneic Hematopoietic Cell Transplantation
Tomomi Toubai*,1,2, Sophie Paczesny1, Yusuke Shono2, Junji Tanaka2, Kathleen P. Lowler1,
Chelsea T. Malter1, Masaharu Kasai3 and Masahiro Imamura2
1Blood and Marrow Transplantation Program, Department of Internal Medicine, Division of Hematology/Oncology,
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; 2Department of Hematology and Onco-
logy, Hokkido University Graduate School of Medicine, Sapporo, Japan; 3Department of Hematology, Sapporo Hokuyu
Hospital, Sapporo, Japan
Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapy for hematological malignan-
cies and inherited diseases. However, acute graft-versus-host-disease (aGVHD) is a major life-threatening complication
after allo-HCT and there are few therapeutic options for severe steroid-refractory aGVHD. Preliminary studies on co-
transplantation of mesenchymal stem cells (MSCs) have shown an improvement in or resolution of severe aGVHD. How-
ever, the underlying mechanism this immunosuppressive effect has not been elucidated. Most of the data suggest that this
immunosuppressive effect involves soluble factors such as IL-6 or TGF-? as well as cell-cell contact dependence.
MSCs interact either directly with T cells or indirectly via other immune cells such as dendritic cells and NK cells. Here
we review the immunomodulatory function of MSCs in allo-HCT and their potential usefulness in the treatment or pre-
vention of severe acute GVHD.
Keywords: Mesenchymal stem cells (MSCs), acute graft-versus-host disease (aGVHD), allogeneic hematopoietic cell trans-
plantation (Allo-HCT), steroid-refractory acute GVHD.
Fridenstein in the late 1960’s as the source of osteoblastic,
adipogenic, and chondrogenic cells in adult bone marrow
. Since then, MSCs have been found in other human tis-
sues, including peripheral blood , liver , fetal lung 
and umbilical cord blood . Subsequently, it has been
demonstrated that MSCs are present in all human tissues [6,
7]. Possible avenues of MSC research have recently been
multiplied in an allogeneic hematopoietic cell transplantation
(allo-HCT) setting because MSCs have the ability not only
to support hematopoiesis but also to regulate immune re-
sponses. In the latter case, Le Blanc et al. reported in 2004
successful treatment by haploidentical third party MSCs in a
patient with steroid-resistant acute GVHD . Subsequently,
a clinical trial was initiated in Europe and encouraging re-
sults have recently been published . The relationship be-
tween MSCs and immunomodulatory functions has been
described in detail in several recent reviews [10-17]. Herein,
we review the major immunomodulatory effects of MSCs
and focus on the narrow field of treatment and prevention of
acute GVHD with MSCs.
Mesenchymal stem cells (MSCs) were first identified by
IMMUNOSUPPRESSIVE EFFECTS OF MSCs
1. MSC Phenotype
human and mouse MSC studies by surface expression of
*Address correspondence to this author at the Blood and Marrow Trans-
plantation Program, University of Michigan Comprehensive Cancer Cen-
ter 1500 E. Medical Center Drive, 6411 CGC Ann Arbor, Michigan 48109-
0942, USA; Tel: (734) 615-7128; Fax: (734) 647-9271;
E-mail: firstname.lastname@example.org and email@example.com
The phenotype of MSCs has been characterized in both
CD29, CD44, CD58, CD71, CD73, CD90, CD105, CD166,
CD271, MHC class I and recently CD146 at the surface of a
sub-endothelial subset and by the absence of expression of
CD34, CD80, CD86, CD40 and HLA class II expression [18,
19]. The variability in expression of these markers may de-
pend on species differences, tissue source and culture condi-
2. MSC Immune Targets
fect of MSCs suggested direct interaction between MSCs
and T lymphocytes. MSCs directly suppress the proliferation
of both naïve and memory lymphocytes T cells via cell-cell
contact or mitogenic stimuli [20-22]. This suppression is not
MHC-restricted. MSCs can decrease IFN-? producing T cells
and skew the T cell population towards Th2 cells producing
Regulatory T Cells
Generation of CD4+CD25+ regulatory T cells (Tregs) in
the presence of MSCs is still controversial. In early studies,
no association with Tregs was observed [20-22]. Later stud-
ies suggested that Tregs are directly generated in the pres-
ence of MSCs [24-26]. However, using a Foxp3sf mouse
model, Parekkadan et al. found that the immunosuppressive
function of MSCs is not associated with Tregs . In addi-
tion, CD8+ regulatory T cells have been shown to play a role
in MSC-mediated immunosuppressive effects . MSCs
have been reported to trigger the generation of Tregs indi-
rectly, often through the intervention of tolerogenic antigen-
presenting cells as described below. Several studies have
shown an interaction between MSC and antigen-presenting
Early studies demonstrating the immunosuppressive ef-
GVHD Treatment by MSCs Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 253
tremely potent antigen-presenting cells (APCs) that play a
major role in the processing and presentation of antigens to
different immune cells and have the unique capacity to prime
naïve T lymphocytes [29, 30]. MSCs were first shown to
strongly inhibit alloantigen-induced DC1 differentiation and
indirectly induce CD4+CD25+ Tregs . MSCs were subse-
quently shown to inhibit the differentiation, function and
migration of both monocyte-derived DCs [23,31-34] and
CD34+-derived DCs [35, 36] by inhibiting the expression of
their co-stimulatory molecules, CD40, CD80, CD83 and
CD86, decreasing secretion of IL-12 and inhibiting mixed
lymphocyte reaction (MLR). The mechanism of the inhibi-
tory effect of MSCs on DCs function is controversial. MSCs
have been reported to increase IL-10 production by mature
DC2  or to inhibit the differentiation to DC1 with an
enhancement of differentiation of CD4+CD25+ Tregs .
More recently, Li et al. reported that human DCs generated
in co-culture with MSC have immunosuppressive effects
mediated through activation of the Notch pathway,  and
Zhang et al. reported that mouse bone marrow-derived
MSCs induce the differentiation of DCs into Jagged-2-
dependent regulatory DCs . Regarding inhibitory effects
on migration, English et al. showed that MSCs decreased
CCR7 surface expression on DCs and subsequently their
functional migration to CCL19 . However, details of the
molecular interactions between MSCs and DCs remain un-
clear. Macrophages might also be a target of MSCs, since
Nemeth et al. have recently shown that administration of
cultured human bone marrow-derived MSCs reduced mortal-
ity and improved organ function of septic mice, through in-
creases in PGE2 and IL-10 by macrophages .
Dendritic cells (DCs) represent a rare population of ex-
[23, 40-44]. MSCs can inhibit IL-2-induced NK cell prolif-
eration [43, 44] via activation of indoleamine 2,3-
dioxygenase (IDO) and prostaglandin E2 (PGE2) . MSCs
also inhibit the cytolytic function and IFN-? production of
NK cells [23, 42]. Downregulation of NK receptors (NKp30,
NKp44 and NKG2D) has been suggested to be responsible
for the decreased NK cell functions .
Effects of MSCs on NK cells have also been reported
experimental model for human systemic lupus erythematous,
showed inhibition of the proliferation, activation and IgG
secretion of B cells in the presence of allogeneic MSCs .
Corcione et al. have further shown that MSCs not only in-
hibit B cell proliferation and differentiation to antibody-
producing cells but also chemotaxis in vitro . MSCs may
play this role through STAT3 inactivation and PAX5 induc-
tion . These recent findings contradict results of previous
studies suggesting that MSCs induce the proliferation of
memory B cells and their differentiation into plasma cells
[48, 49]. Further analyses are therefore required.
3. Mechanisms of MSC-Mediated Immunosuppressive
Results of a study by Deng et al. using BXSM mice, an
into two types: soluble factor-mediated effects and cell-cell
MSC-mediated immunosuppressive effects are classified
TGF-?, hepatocyte growth factor (HGF), IDO, PGE2 and
heme oxygenase-1 (HO-1), have been implicated in the im-
munosuppressive effects of MSCs, though the exact mecha-
nism is still unclear [22,23,32,50-53]. For instance, human
MSCs decreased tumor necrosis factor ? (TNF?) secretion
from mature DC1 and IFN-? secretion from NK cells, in-
creased IL-10 secretion from mature DC2 and induced T cell
polarization from Th1 to Th2, which are supposedly induced
by elevated PGE2 production from MSCs . MSCs resid-
ing in the lung also have an immunosuppressive effect that is
associated with increased secretion of PGE2 in response to
IL-1? . The role of IDO in the immunosuppressive effect
of MSCs is controversial. Prior studies have shown a posi-
tive association between IDO and the immunosuppressive
effects of MSCs, particularly NK cells inhibition [43, 53]
whereas two recent studies have shown a negative associa-
tion [54, 55]. Min et al. examined the role of IL-10 in the
immunosuppressive effects of MSCs using IL-10-transduced
MSCs in a GVHD mouse model and showed that co-
injection of IL-10-transduced MSCs reduced GVHD severity
and prolonged survival . However, a significant effect of
IL-10 was not found in other studies [35, 54]. Djouad et al.
suggested that IL-6 is involved because murine MSCs se-
creted an appreciable amount of IL-6 and its neutralization
resolved this immunosuppressive effect . Recently, two
studies have shown a correlation between nitric oxide (NO)
and MSC-mediated immunosuppression [54, 55]. NO is pro-
duced by NO synthases (NOSs) and has three subtypes: in-
ducible NOS (iNOS), endothelial NOS, and neuronal NOS.
Sato et al. reported that NO produced by MSCs plays a ma-
jor role in T cell suppression through the suppression of
Stat5 phosphorylation . Ren et al. showed in both in
vitro and in vivo models of GVHD that the immunosuppres-
sive function of MSCs was elicited by iNOS and chemoki-
nes induced by INF-? with concomitant presence of either
TNF-?, IL-1? or IL-1? . Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) has no effect on prolif-
eration or differentiation of MSCs but does promote the mi-
gration of human MSCs .
Cell-cell contact-mediated effects were first suggested by
the finding that addition of few MSCs in co-culture did not
inhibit an MLR, whereas addition of larger numbers of
MSCs resulted in strong suppression of the MLR . In
addition, Di Nicola et al. clearly showed that MSCs directly
suppress the proliferation of T cells via cell-cell contact .
The cell-cell contact between MSCs and targets cells by en-
gagement of PD1 and its ligand is also a mechanism for in-
hibition of T cell proliferation . Toll-like receptors have
recently been shown to be associated with inhibition of T
cell function by MSCs [61-64]. Selmani et al. found that
secretion by MSCs of HLA-G5, a tolerogenic non-classical
MHC class?Ib molecule, was critical for reducing allogeneic
T cell proliferation, inhibition of NK cell function, and ex-
pansion of Tregs .
Soluble factors, such as Th2 cytokines (IL-10 and IL-4),
ated with cell cycle arrest of T cells, inducing their anergy.
Glennie et al. found that the lack of early activation of T
cells is due to down-regulation of cyclin D2 expression and
increased levels of p27Kip1 (cyclin-dependent kinase inhibi-
tor). Cyclin D2 is a marker of early G1 phase and inhibition
of its expression is associated with T cell arrest at this stage
On the other hand, MSCs have been shown to be associ-
254 Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 Toubai et al.
. Ramasamy et al. have shown that MSCs blocked DCs
from entering into G1 phase, causing an accumulation of
cells in G0 phase .
4. In Vivo Prevention and Treatment of GVHD Using
MSCs differ from in vitro studies in several ways. Although
MSCs have an immunosuppressive function in vitro, there
are not many in vivo experimental data to support this. Table
1 summarizes studies using mouse models. The first study
using a mouse model was by Chung et al. in 2004, and their
study showed that co-transplantation of MSCs prevented
lethal GVHD in a major histocompatibility complex (MHC)-
mismatched model . Later, Yanez et al. reported that
adipose derived-MSCs could also prevent GVHD . The
mechanisms involved are IFN-? activation of MSCs  and
increase of CD4+CD25+ T cells . On the other hand, Su-
dres et al. did not detect any significant difference between
the treated group and control group in a study using an
MHC-mismatched model in which MSCs were injected be-
fore BMT (one injection) . Tisato et al. demonstrated
prevention of GVHD in their xenogenic model using 4
weekly MSC injections instead of a single injection, but
when MSCs were injected at the onset of GVHD, they could
not find any significant effect . Badillo et al. also re-
ported the failure of prevention of GVHD by treatment with
MSCs in their haploidentical mouse model,  although the
experimental procedure they used was the same as that used
by Yanez et al. One possible reason for this discrepancy in
results may be the difference in tissue of origin: adipose tis-
sues versus bone marrow. The latter authors have also re-
ported that allogeneic MSCs could not induce tolerance in a
skin graft . Possible explanations for the variability of
these results are: (i) the timing of injection possibly due to
the milieu of cytokines present as this time, (ii) the dose of
MSCs used, (iii) MSC tissue of origin, (iv) strain differences
between donor and host and (v) possible rejection of MSCs
In vivo studies on the immunosuppressive function of
shortly after injection (by an unknown mechanism). Further
discernment of the critical parameters will require additional
in vivo studies.
5. Clinical Application of MSCs After Allo-HCT
MSCs that were expanded ex vivo was a safe treatment for
15 patients with hematological malignancies in complete
remission . Other clinical studies using MSCs were per-
formed in advanced breast cancer patients for promoting
rapid hematopoietic recovery after autologous stem cell
transplantation . Lazarus et al. also reported the results
of an open-label, multicenter study on safety and feasibility
of co-transplantation of HLA-identical expanded MSCs in
46 patients with hematological malignancies after a myelo-
ablative conditioning regimen. However, the engraftment of
neutrophils and platelets was similar to historical reports (at
days 14 and 20, respectively) . In contrast, Le Blanc et
al. reported in 2007 that co-transplantation of MSCs en-
hanced the engraftment of hematopoietic stem cells after
allo-HCT in 7 patients in comparison to their historical con-
trols . Co-transplantation of ex vivo-expanded MSCs for
prevention of graft failure in haploidentical allo-HCT
showed no graft failure in the treated group versus 14.9%
graft failure in the historical group and faster recovery of
total leukocyte count and NK cells . Macmillan et al.
have recently confirmed the safety of transplantation of ex-
vivo culture-expanded parental haploidentical MSCs in pedi-
atric recipients of unrelated donor umbilical cord blood with
good engraftment parameters .
Lazarus et al. demonstrated that infusion of autologous
9-year-old boy with steroid-refractory grade IV aGVHD
involving the gut and liver was successfully treated with
MSCs derived from a haplo-identical donor . His symp-
toms dramatically improved after administration of the first
dose. This case report was followed by a pilot study using
MSCs to treat steroid-refractory GVHD after allo-HCT .
Nine patients (8 patients with steroid refractory acute GVHD
Regarding GVHD, Le Blank et al. reported in 2004 that a
The Prevention and Prophylaxis of Acute GVHD in Murine Models
Authors Source of MSCs Model of Mice Conditioning Dose of MSCs Results
Chung et al.
1x105 GVHD prevented
Yanez et al.
GVHD prevented by administration at day
0, 7, and 14
Sudres et al.
T cells 5x105
5x105, 3x106, 4x106 No prevention of GVHD
Tisato et al.
PBMC 2x107 3x106 Single dose, no GVHD prevention,
4 times, GVHD prevention
After onset GVHD, no efficacy
Badillo et al.
1.5x105- 1x106 (once)
5x104 (3 times)
GVHD prevention; no efficacy
GVHD prevention; no efficacy
GVHD treatment; no efficacy
Polchert et al.
Success by administration at day 2 and day
20, but the BMT from IFN-?-/- donor was
BM, bone marrow; PBMC, peripheral blood mono nuclear cells.
GVHD Treatment by MSCs Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 255
and 1 patient with chronic GVHD) were treated with MSCs
derived from an HLA identical sibling (n=2), haploidentical
donor (n=5) and HLA-mismatched donor (n=4), resulting in
the disappearance of acute GVHD in six of the eight pa-
tients; two died soon after MSC administration with no re-
sponse. Overall survival (OS) was significantly better in the
MSC-treated group than in the control group, although 2 of
the 6 patients with complete responses developed pneumonia
and bronchiolitis. Fang et al. also reported some success
using human adipose tissue-derived MSCs for treatment of
steroid-refractory GVHD [82-84]. Muller et al. reported re-
sults of 11 infusions of expanded MSCs to treat acute
GVHD, chronic GVHD, hemophagocytosis and graft rejec-
tion after allo-HCT  showing a moderate response in
patients with acute and chronic GVHD. Le Blanc et al. re-
ported the results of a phase II?multicenter study for treat-
ment of steroid-refractory severe acute GVHD with ex-
panded MSCs . A total of 55 patients received treatment
(20 patients receiving a single infusion, 22 receiving 2 infu-
sions, and 6 receiving 3-5 infusions). Thirty patients showed
a complete response and nine patients showed partial re-
sponse, an overall response rate of 71%. There was a signifi-
cant improvement in 2-year OS in the complete response
group (53%) and a significant decrease in 1-year transplant-
related mortality (TRM) (37%). These encouraging results
could not be reproduced in a study by von Bonin et al. that
included 13 patients with steroid-refractory aGVHD treated
with third-party MSCs; only 2 patients (15%) responded and
did not require further escalation of immunosuppressive
therapy . The donor source of MSCs might account for
these differences, and studies addressing this question are
required. Regarding GVL effects, three patients had recur-
rent malignant disease and one developed de novo acute
myeloid leukemia of recipient origin. As for infections, 16
patients (29%) developed various infections, including as-
pergillosis, cytomegalovirus, and septicemia (caused by En-
terococci, Klebsiella sp, Escherichia coli, and unidentified
pathogens), and three patients developed infection with Ep-
stein-Barr virus (EBV), one of which developed post-
transplantation lymphoproliferative disease related to the
prophylaxis of GVHD are summarized in Table 2. However,
since other immunosuppressants such as steroids were used
in all of those studies, we are unable to distinguish between
the effects induced by MSCs and those induced by the im-
The results of several clinical studies on treatment and
6. Controversy About the Use of MSCs After Allo-HCT
steroid-refractory GVHD. However, some controversy has
resulted this approach; some may be resolved, some will
require further analysis.
a. Absence of MHC-Restriction and MSC Donor Source
MSCs might be an attractive option for the treatment of
MHC recognition, suggesting that MSCs lack specificity,
creating the problem of a global immunosuppression. Fur-
thermore, results obtained using different donor sources of
MSCs (haploidentical MSCs, third party MSCs or identical
Immunosuppression via MSCs is not mediated through
MSCs) are not clear. This question should be answered by
future in vivo studies and trials.
b. Absence of In Vivo Detection
ministered in vivo, preventing any biological measurement of
the efficacy of treatment. The only human study which could
successfully detect gene marked MSCs dealt with engraft-
ment in children with osteogenesis imperfecta .
c. Transformation and Facilitation of Primary Disease
MSCs have been almost impossible to detect when ad-
culture, murine bone marrow-derived MSCs transformed
into malignant fibrosarcoma with chromosomal abnormali-
ties, elevated telomerase activity, and increased expression
of c-myc . Tolar et al. reported the development of sar-
coma in mice after injection of cultured MSCs . In con-
trast, Bernardo et al. demonstrated that human bone marrow-
derived MSCs did not have a risk for malignant transforma-
tion, even after several passages . However, long-term
follow-up observations for the development of secondary
malignancies after co-transplantation of MSCs are needed.
MSCs also have the potential to promote tumor growth in
vivo . Since GVHD is closely associated with GVL, we
must confirm whether the GVL effect is decreased after in-
fusion of MSCs, particularly in the high relapse risk patient
group. In fact, Ning et al. reported significantly higher rates
of relapse which developed faster in the group co-
transplanted with MSCs than in the untreated group, al-
though GVHD was decreased . However, in this study
(i) the population was small, (ii) few MSCs were infused so
the correlation is not clear, and (iii) the disease status at
transplant is unknown. In addition, according to Le Blanc’s
finding, only 3 of 55 patients had recurrent malignancies at
the 2 years follow-up . Therefore, we must monitor pri-
mary malignant disease closely, especially in patients with a
high risk of relapse, and confirm the safety and efficacy of
treatment using large-scale randomized studies.
d. Global Immunosuppression and Infections
Miura et al. demonstrated that after several passages in
severe infections [9,75,78,79,81-85,92,93]. However, some
have found a correlation between MSC treatment and the
occurrence of infections. Kang et al. demonstrated that
MSCs suppress approximately 50% of virus-induced CTLs,
 and Sundin et al. examined whether MSCs can be in-
fected with cytomegarovirus, HSV-1, HSV-2, EBV, or
varicella-zoster virus (VZV). Although herpes family viruses
were not detected by PCR in ex vivo-expanded MSCs de-
rived from seropositive donors, MSCs could be infected in
vitro with CMV and HSV-1, but not EBV . There was a
suppression of the lymphocyte proliferative response to
HSV, candida, and bacteria infection . Conversely,
Karlsson et al. demonstrated that MSCs did not affect on
EBV and CMV T cell responses in vitro and in vivo, sup-
pressing only the alloantigen response . Persistent par-
vovirus B19 in MSCs can also infect hematopoietic stem
cells . However, recently, septic mice had improved or-
gan failure and mortality rates after administration of MSCs
cultured from mouse bone marrow . Thus, the associa-
tion between increased incidence of infection and MSCs
Previous clinical studies have shown no increased risk of
256 Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 Toubai et al.
remains controversial, and we should remember this uncer-
tainty in treating steroid-refractory GVHD.
e. Efficacy Without Other Immunosuppressants
other immunosuppressants such as tacrolimus, cyclosporine,
mycophenolate mofetil, and sirolimus. Therefore, the effi-
cacy of MSCs should be assessed accordingly. For instance,
in a heart transplant model, Hoogduijn et al. found that
therapeutic doses of mycophenolate mofetil and sirolimus
inhibited MSC proliferation, and high doses of tacrolimus
In many clinical situations, MSCs are administered with
significantly reduced the number of viable MSCs . Con-
versely, MSCs had an adverse effect on the immunosuppres-
sive efficacy of tacrolimus and sirolimus. This might be dif-
ferent if MSCs are isolated from bone marrow. In conclu-
sion, we need to be cautious when using a combination of
MSCs and other immunosuppressants.
oid-refractory GVHD patients. Although steroid administra-
MSCs are an attractive alternative for treatment of ster-
The Clinical Study for Treatment and Prophylaxis of GVHD in Allo-HSCT
Authors Source MSC donor
Number of patients
Conditioning Dose of MSCs Effect on GVHD
et al. 
1 (9-year-old boy) /
Grade4?improved? Reccurence? improved
et al. 
9 (12 times infu-
acute GVHD 8,
Complete response 6, Response of GVHD 1,
Slight effect 1, No response 4
Fang, et al.
2 / steroid-refractory
1 / chronic hepatic
6 / steroid-refractory
5/6 complete response
Muller, et al.
7 (11 times infu-
/ aGVHD n=2,
0.4-3x106/kg aGVHD, 1/2 alive and well
cGVHD, 1/3 slightly improved
Hemophagocytosis, good response
Graft rejection prophylaxis, alive and well
et al. 
55 (92 infusions
/ Grade 2 n=5,
Grade 3 n=25,
Grade 4 n=25
Children: complete response 17/25, partial
Adult: complete response 13/30, partial re-
Total: complete response 30/55 (54.5%),
partial response 9/55 (16.3%)
One year transplantation related mortality
37% (complete response) vs 72% (partial or
Overall survival at 2 years 53% (complete
response) vs 16% (partial or no response)
et al. 
13 (32 infusions)/
Grade 3 n=2, Grade
2 patients (15%) responded within a week
after first MSC infusion.
5/11 (45%) patients showed a response after
received additional salvage immunosuppres-
sive therapy with MSC infusion
BM, bone marrow: RIC, reduced-intensity conditioning.
GVHD Treatment by MSCs Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 257
tion is the mainstay treatment for aGVHD, there are many
adverse side-effects. Therefore, treatment using MSCs with
new compounds has become the hope of many clinicians.
Although the European clinical study results are encourag-
ing, they need to be confirmed by a phase III trial. Since
mouse models are controversial and depend on experimental
conditions, the biologic mechanisms induced by MSCs in
vivo should be further evaluated. The acceptance and promo-
tion of this treatment will depend on (i) more basic research
conducted under clinically relevant conditions, (ii) the stan-
dardization of MSC culture protocol, and (iii) validation by
several large-scale multi-institutional clinical trials.
Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Het-
erotopic of bone marrow. Analysis of precursor cells for osteogenic
and hematopoietic tissues. Transplantation 1968; 6: 230-47.
Huss R, Lange C, Weissinger EM, Kolb HJ, Thalmeier K. Evi-
dence of peripheral blood-derived, plastic-adherent CD34(-/low)
hematopoietic stem cell clones with mesenchymal stem cell charac-
teristics. Stem Cells 2000; 18: 252-60.
Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I,
Fisk NM. Identification of mesenchymal stem/progenitor cells in
human first-trimester fetal blood, liver, and bone marrow. Blood
2001; 98: 2396-402.
in 't Anker PS, Noort WA, Scherjon SA, et al. Mesenchymal stem
cells in human second-trimester bone marrow, liver, lung, and
spleen exhibit a similar immunophenotype but a heterogeneous
multilineage differentiation potential. Haematologica 2003; 88:
Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in
human umbilical cord blood. Br J Haematol 2000; 109: 235-42.
da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal
stem cells reside in virtually all post-natal organs and tissues. J Cell
Sci 2006; 119: 2204-13.
Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mes-
enchymal stem cells in multiple human organs. Cell Stem Cell
2008; 3: 301-13.
Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe
acute graft-versus-host disease with third party haploidentical mes-
enchymal stem cells. Lancet 2004; 363: 1439-41.
Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for
treatment of steroid-resistant, severe, acute graft-versus-host dis-
ease: a phase II study. Lancet 2008; 371: 1579-86.
Bacigalupo A. Mesenchymal stem cells and haematopoietic stem
cell transplantation. Best Pract Res Clin Haematol 2004; 17: 387-
Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem
cells and clinical experience. J Intern Med 2007; 262: 509-25.
Ozawa K, Sato K, Oh I, et al. Cell and gene therapy using mesen-
chymal stem cells (MSCs). J Autoimmun 2008; 30: 121-7.
Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological
properties of mesenchymal stem cells and clinical implications.
Arch Immunol Ther Exp (Warsz). 2008; 56: 1-8.
Dazzi F, Marelli-Berg FM. Mesenchymal stem cells for graft-
versus-host disease: close encounters with T cells. Eur J Immunol
2008; 38: 1479-82.
Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new
strategy for immunosuppression? Trends Immunol 2007; 28: 219-
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health
and disease. Nat Rev Immunol 2008; 8: 726-36.
Nauta AJ, Fibbe WE. Immunomodulatory properties of mesen-
chymal stromal cells. Blood 2007; 110: 3499-506.
Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the
nomenclature for MSC: The International Society for Cellular
Therapy position statement. Cytotherapy 2005; 7: 393-5.
Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteopro-
genitors in bone marrow sinusoids can organize a hematopoietic
microenvironment. Cell 2007; 131: 324-36.
Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow
stromal cells suppress T-lymphocyte proliferation induced by cellu-
lar or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-43.
Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem
cells suppress lymphocyte proliferation in vitro and prolong skin
graft survival in vivo. Exp Hematol 2002; 30: 42-8.
Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchy-
mal stem cells inhibit the response of naive and memory antigen-
specific T cells to their cognate peptide. Blood 2003; 101: 3722-9.
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modu-
late allogeneic immune cell responses. Blood 2005; 105: 1815-22.
Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of
mesenchymal stem cells prolongs the survival of a semiallogeneic
heart transplant through the generation of regulatory T cells. J Im-
munol 2008; 181: 3933-46.
Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 se-
cretion by human mesenchymal stem cells is required to suppress T
lymphocyte and natural killer
CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26:
Maccario R, Podesta M, Moretta A, et al. Interaction of human
mesenchymal stem cells with cells involved in alloantigen-specific
immune response favors the differentiation of CD4+ T-cell subsets
expressing a regulatory/suppressive phenotype. Haematologica
2005; 90: 516-25.
Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived
mesenchymal stem cells ameliorate autoimmune enteropathy inde-
pendently of regulatory T cells. Stem Cells 2008; 26: 1913-9.
Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Genera-
tion of CD4+ or CD8+ regulatory T cells upon mesenchymal stem
cell-lymphocyte interaction. Haematologica 2007; 92: 881-8.
Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic
cells. Annu Rev Immunol 2000; 18: 767-811.
Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage,
plasticity and cross-regulation. Nat Immunol 2001; 2: 585-9.
Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal
stem cells alter antigen-presenting cell maturation and induce T-
cell unresponsiveness. Blood 2005; 105: 2214-9.
Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal
stem cells require monocyte-mediated activation to suppress allore-
active T cells. Exp Hematol 2005; 33: 928-34.
Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells
inhibit differentiation and function of monocyte-derived dendritic
cells. Blood 2005; 105: 4120-6.
Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on
differentiation, maturation, and function of human monocyte-
derived dendritic cells. Stem Cells Dev 2004; 13: 263-71.
Li YP, Paczesny S, Lauret E, et al. Human mesenchymal stem cells
license adult CD34+ hemopoietic progenitor cells to differentiate
into regulatory dendritic cells through activation of the Notch
pathway. J Immunol 2008; 180: 1598-608.
Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE.
Mesenchymal stem cells inhibit generation and function of both
CD34+-derived and monocyte-derived dendritic cells. J Immunol
2006; 177: 2080-7.
Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce ma-
ture dendritic cells into a novel Jagged-2-dependent regulatory
dendritic cell population. Blood 2009; 113: 46-57.
English K, Barry FP, Mahon BP. Murine mesenchymal stem cells
suppress dendritic cell migration, maturation and antigen presenta-
tion. Immunol Lett 2008; 115: 50-58.
Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow
stromal cells attenuate sepsis via prostaglandin E(2)-dependent re-
programming of host macrophages to increase their interleukin-10
production. Nat Med 2009; 15: 42-9.
Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma
in the immunomodulatory activity of human bone marrow mesen-
chymal stem cells. Stem Cells 2006; 24: 386-98.
Poggi A, Prevosto C, Zancolli M, Canevali P, Musso A, Zocchi
MR. NKG2D and natural cytotoxicity receptors are involved in
natural killer cell interaction with self-antigen presenting cells and
stromal cells. Ann N Y Acad Sci 2007; 1109: 47-57.
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papa-
michail M. Interactions between human mesenchymal stem cells
and natural killer cells. Stem Cells 2006; 24: 74-85.
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari
MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell
proliferation, cytotoxicity, and cytokine production: role of in-
function and to induce
258 Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 Toubai et al.
doleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008;
Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta
L. Mesenchymal stem cell-natural killer cell interactions: evidence
that activated NK cells are capable of killing MSCs, whereas MSCs
can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107:
Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of
allogeneic bone marrow-derived mesenchymal stem cells on T and
B lymphocytes from BXSB mice. DNA Cell Biol 2005; 24: 458-
Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal
stem cells modulate B-cell functions. Blood 2006; 107: 367-72.
Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cell-
derived CCL2 suppresses plasma cell immunoglobulin production
via STAT3 inactivation and PAX5 induction. Blood 2008; 112:
Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal
stem cells stimulate antibody secretion in human B cells. Scand J
Immunol 2007; 65: 336-43.
Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesen-
chymal stem cells induce both polyclonal expansion and differen-
tiation of B cells isolated from healthy donors and systemic lupus
erythematosus patients. Stem Cells 2008; 26: 562-9.
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Sup-
pression of allogeneic T-cell proliferation by human marrow stro-
mal cells: implications in transplantation. Transplantation 2003; 75:
Chabannes D, Hill M, Merieau E, et al. A role for heme oxygenase-
1 in the immunosuppressive effect of adult rat and human mesen-
chymal stem cells. Blood 2007; 110: 3691-4.
Jarvinen L, Badri L, Wettlaufer S, et al. Lung resident mesenchy-
mal stem cells isolated from human lung allografts inhibit T cell
proliferation via a soluble mediator. J Immunol 2008; 181: 4389-
Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D.
Human bone marrow stromal cells inhibit allogeneic T-cell re-
sponses by indoleamine 2,3-dioxygenase-mediated tryptophan deg-
radation. Blood 2004; 103: 4619-21.
Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated
immunosuppression occurs via concerted action of chemokines and
nitric oxide. Cell Stem Cell 2008; 2: 141-50.
Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in
suppression of T-cell proliferation by mesenchymal stem cells.
Blood 2007; 109: 228-34.
Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone
marrow mesenchymal stem cells can attenuate the severity of acute
graft-versus-host disease after experimental allogeneic stem cell
transplantation. Bone Marrow Transplant 2007; 39: 637-45.
Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem
cells inhibit the differentiation of dendritic cells through an inter-
leukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-32.
Secchiero P, Melloni E, Corallini F, et al. Tumor necrosis factor-
related apoptosis-inducing ligand promotes migration of human
bone marrow multipotent stromal cells. Stem Cells 2008; 26: 2955-
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O.
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte
cultures and mitogenic responses independently of the major histo-
compatibility complex. Scand J Immunol 2003; 57: 11-20.
Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal
progenitor cells inhibit lymphocyte proliferation by activation of
the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-
Hwa Cho H, Bae YC, Jung JS. Role of toll-like receptors on human
adipose-derived stromal cells. Stem Cells 2006; 24: 2744-52.
Liotta F, Angeli R, Cosmi L, et al. Toll-like receptors 3 and 4 are
expressed by human bone marrow-derived mesenchymal stem cells
and can inhibit their T-cell modulatory activity by impairing Notch
signaling. Stem Cells 2008; 26: 279-89.
Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like
receptors and their ligands control mesenchymal stem cell func-
tions. Blood 2007; 109: 1422-32.
Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka
ES, Scandurro AB. Toll-like receptors on human mesenchymal
stem cells drive their migration and immunomodulating responses.
Stem Cells 2008; 26: 99-107.
Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow
mesenchymal stem cells induce division arrest anergy of activated
T cells. Blood 2005; 105: 2821-7.
Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G,
Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentia-
tion and function by preventing entry into the cell cycle. Transplan-
tation 2007; 83: 71-6.
Chung NG, Jeong DC, Park SJ, et al. Cotransplantation of marrow
stromal cells may prevent lethal graft-versus-host disease in major
histocompatibility complex mismatched murine hematopoietic
stem cell transplantation. Int J Hematol 2004; 80: 370-6.
Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M,
Bueren JA. Adipose tissue-derived mesenchymal stem cells have in
vivo immunosuppressive properties applicable for the control of the
graft-versus-host disease. Stem Cells 2006; 24: 2582-91.
Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of
mesenchymal stem cells for treatment and prevention of graft ver-
sus host disease. Eur J Immunol 2008; 38: 1745-55.
Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived
mesenchymal stem cells decrease acute graft-versus-host disease
after allogeneic hematopoietic stem cells transplantation. Immunol
Invest 2008; 37: 29-42.
Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal
stem cells suppress lymphocyte proliferation in vitro but fail to
prevent graft-versus-host disease in mice. J Immunol 2006; 176:
Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesen-
chymal stem cells of cord blood origin are effective at preventing
but not treating graft-versus-host disease. Leukemia 2007; 21:
Badillo AT, Peranteau WH, Heaton TE, Quinn C, Flake AW. Mur-
ine bone marrow derived stromal progenitor cells fail to prevent or
treat acute graft-versus-host disease. Br J Haematol 2008; 141:
Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Mur-
ine bone marrow stromal progenitor cells elicit an in vivo cellular
and humoral alloimmune response. Biol Blood Marrow Transplant
2007; 13: 412-22.
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan
AI. Ex vivo expansion and subsequent infusion of human bone
marrow-derived stromal progenitor cells (mesenchymal progenitor
cells): implications for therapeutic use. Bone Marrow Transplant
1995; 16: 557-64.
Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic re-
covery after coinfusion of autologous-blood stem cells and culture-
expanded marrow mesenchymal stem cells in advanced breast can-
cer patients receiving high-dose chemotherapy. J Clin Oncol 2000;
Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of
HLA-identical sibling culture-expanded mesenchymal stem cells
and hematopoietic stem cells in hematologic malignancy patients.
Biol Blood Marrow Transplant 2005; 11: 389-98.
Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of
mesenchymal stem cells to enhance engraftment of hematopoietic
stem cells. Leukemia 2007; 21: 1733-8.
Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex
vivo expanded mesenchymal stem cells accelerates lymphocyte re-
covery and may reduce the risk of graft failure in haploidentical
hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-7.
Macmillan ML, Blazar BR, Defor TE, Wagner JE. Transplantation
of ex-vivo culture-expanded parental haploidentical mesenchymal
stem cells to promote engraftment in pediatric recipients of unre-
lated donor umbilical cord blood: results of a phase I-II clinical
trial. Bone Marrow Transplant 2008; 149(9 Supple): 16-22.
Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells
for treatment of therapy-resistant graft-versus-host disease. Trans-
plantation 2006; 81: 1390-7.
Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to
human adipose tissue-derived mesenchymal stem cells in steroid-
refractory acute graft-versus-host disease. Transplant Proc 2007;
Fang B, Song Y, Lin Q, et al. Human adipose tissue-derived mes-
enchymal stromal cells as salvage therapy for treatment of severe
GVHD Treatment by MSCs Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 4 259
refractory acute graft-vs.-host disease in two children. Pediatr
Transplant 2007; 11: 814-7.
Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe
therapy-resistant acute graft-versus-host disease with human adi-
pose tissue-derived mesenchymal stem cells. Bone Marrow Trans-
plant 2006; 38: 389-90.
Muller I, Kordowich S, Holzwarth C, et al. Application of multipo-
tent mesenchymal stromal cells in pediatric patients following allo-
geneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-
von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory
acute GVHD with third-party MSC expanded in platelet lysate-
containing medium. Bone Marrow Transplant 2009; 43: 245-51.
Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone
marrow-derived mesenchymal cells engraft and stimulate growth in
children with osteogenesis imperfecta: Implications for cell therapy
of bone. Proc Natl Acad Sci USA 2002; 99: 8932-7.
Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromo-
somal instability in murine bone marrow mesenchymal stem cells
leads to malignant transformation. Stem Cells 2006; 24: 1095-103.
Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cul-
tured mesenchymal stem cells. Stem Cells 2007; 25: 371-9.
Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow
derived mesenchymal stem cells do not undergo transformation af-
ter long-term in vitro culture and do not exhibit telomere mainte-
nance mechanisms. Cancer Res 2007; 67: 9142-9.
Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of
mesenchymal stem cells favors tumor growth in allogeneic ani-
mals. Blood 2003; 102: 3837-44.
Ning H, Yang F, Jiang M, et al. The correlation between cotrans-
plantation of mesenchymal stem cells and higher recurrence rate in
hematologic malignancy patients: outcome of a pilot clinical study.
Leukemia 2008; 22: 593-9.
Poloni A, Leoni P, Buscemi L, et al. Engraftment capacity of mes-
enchymal cells following hematopoietic stem cell transplantation in
patients receiving reduced-intensity conditioning regimen. Leuke-
mia 2006; 20: 329-35.
Kang HS, Habib M, Chan J, et al. A paradoxical role for IFN-
gamma in the immune properties of mesenchymal stem cells during
viral challenge. Exp Hematol 2005; 33: 796-803.
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le
Blanc K. Mesenchymal stem cells are susceptible to human
herpesviruses, but viral DNA cannot be detected in the healthy se-
ropositive individual. Bone Marrow Transplant 2006; 37: 1051-9.
Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem
cells exert differential effects on alloantigen and virus-specific T-
cell responses. Blood 2008; 112: 532-41.
Hoogduijn MJ, Crop MJ, Korevaar SS, et al. Susceptibility of
human mesenchymal stem cells to tacrolimus, mycophenolic acid,
and rapamycin. Transplantation 2008; 86: 1283-91.
Received: September 29, 2008
Revised: February 04, 2009 Accepted: March 11, 2009